Is erbB-2 a predictive marker for response to primary chemotherapy (CT) for operable breast cancer? Prospective study in a phase III randomized, parallel study of doxorubicin/cyclophosphamide (AC) and doxorubicin/Taxol^( !R)(paclitaxel) (AT)

収録刊行物

• Proc Am Soc Clin Oncol

  Proc Am Soc Clin Oncol 18 85a-, 1999